使用与Gateway技术兼容的T载体获得入门克隆

与Gateway技术兼容的农杆菌双元载体系统已开始应用于植物功能基因组的研究,但应用这些载体系统的一个瓶颈问题,是如何简单、经济和高效地将PCR产物或其他来源的目的DNA片段构建到入门载体上获得入门克隆.为此,将传统的TA克隆技术与Gateway重组克隆技术进行整合,构建了与Gateway技术兼容的两种TA克隆载体,用于在克隆PCR产物或其他来源的目的DNA片段的同时获得入门克隆.利用兼容Gateway技术的TA克隆载体有效地解决了上述瓶颈问题.     

金针菇谷氨酸脱氢酶基因的克隆及原核表达

利用简并引物和RT-PCR方法从金针菇(Flammulina velutipes)幼嫩子实体中克隆获得FvGDH全长cDNA序列.构建入门载体pGWC-FvGDH,利用Gateway克隆技术的LR反应构建原核重组表达载体pDESTl7-FvGDH,转化大肠杆菌BL21(DE3).通过IPTG法诱导表达融合蛋白并进行表达条件优化.SDS-PAGE蛋白电泳分析表明,融合蛋白相对分子质量约为53 kD,与预测的一致.最佳表达条件为温度30℃、IPTG浓度0.4mmol/L、诱导4 h.融合蛋白表达量较高,实现了FvGDH的高效表达,并利用Western blotting对其特异性进行鉴定.FvGDH基因高效原核表达体系的成功建立,为进一步研究FvGDH的酶促动力学奠定了基础.     

布鲁菌抗原的快速克隆与高效表达

目的:通过Gateway技术构建布鲁菌抗原表达载体,并筛选出高效可溶性表达载体。方法:以山羊布鲁菌16M株染色体DNA为模板,扩增4个布鲁菌抗原基因BMEI2002、BMEI1069、BMEI1483和BMEI0748,利用GatewayBP反应将基因克隆到入门载体pDONR201中,构建重组质粒,然后用Gateway LR反应将基因重组到3种表达载体(pDEST17、pHXGWA、pHGGWA)中,构建相应的重组表达质粒,将重组质粒转化大肠杆菌ER2566(DE3)并诱导表达,分析利用3个不同载体所表达蛋白的表达量及表达形式。结果:利用BP反应构建了4个基因的重组质粒,用LR反应将这些基因分别克隆到表达载体,构建得到了相应的表达载体;诱导表达后的可溶性分析显示,含6×His和TRX标签的pHXGWA所表达的蛋白在表达量和可溶性方面均优于pDEST17和pHGGWA。结论:通过Gateway技术实现了布鲁菌抗原的快速克隆,筛选到的pHXGWA可作为后续大规模克隆表达载体,为布鲁菌抗原的大规模克隆表达和保护性抗原的筛选奠定了基础。     

通路克隆入门载体pEN-L4~*-PrbcS-~*T-gfp-L3~*的构建及其应用

为了利用通路克隆(Gateway)技术构建一个含有两个目的基因表达盒的植物表达载体,并把目的基因编码的蛋白质定位到转基因植物的叶绿体中,通过定点突变技术,在含有attL4和attL3重组位点的Gateway入门载体pEN-L4-2-L3中产生HindⅢ和XhoⅠ的酶切位点,然后在这两个酶切位点之间插入一个含有1,5-二磷酸核酮糖羧化酶小亚基的光诱导型启动子(PrbcS)及其叶绿体基质定位序列(*T)和绿色荧光蛋白(GFP)报告基因(gfp)的DNA片段,获得pEN-L4*-PrbcS-*T-gfp-L3*入门载体.用该载体和另一个含有attL1和attL2重组位点的入门载体(pENTR*-PrbcS-*T-gus)与Gateway的目的载体pK7 m34GW2-8 m21GW3进行LR重组反应可以构建一个能串联gfp和gus两个报告基因表达盒的植物表达载体pKm-35S-PrbcS-*T-gfp-PROLD-PrbcS-*T-gus,所构建的植物表达载体转化烟草后,gfp和gus基因能插入到转基因烟草的基因组中并正常表达,所表达的GFP蛋白可正确定位到转基因植物的叶绿体中,而GUS蛋白也可以在叶片中表达.利用此表达载体通过一次转化事件不仅可以完成两个目的基因的转化操作,而且还可以利用叶绿体基质定位序列(*T)把PrbcS控制表达的目的蛋白直接定位到转基因植物的叶绿体中.因此pEN-L4*-PrbcS-*T-gfp-L3*入门载体的应用进一步扩大了Gateway技术及植物表达载体的应用范围,为叶绿体基因工程操作提供了一个更方便的技术平台.     

含有Rubisco小亚基启动子和转运肽序列的通路克隆入门载体的构建和应用

Gateway(通路克隆)技术是最近开发出来的一种分子克隆技术,其特点是操作简单、省时高效,已经成功应用于很多基因表达载体的构建.然而,现有的通路克隆植物表达载体不包含任何将表达蛋白定位到叶绿体中的序列.将通路克隆入门质粒载体pENTR-2B的XmnⅠ位点改造成HindⅢ位点,产生入门载体pENTR*-2B,然后将番茄1,5二磷酸核酮糖羧化酶(Rubisco)小亚基3C的启动子(PrbcS)及其转运肽序列(*T)和绿色荧光蛋白(GFP)报告基因亚克隆到pENTR*-2B中,构建通路克隆入门载体pENTR*-PrbcS-*T-GFP.实验结果证实,用pENTR*-PrbcS-*T-GFP和通路克隆的植物表达载体进行LR反应,构建GFP的光诱导型植物表达载体,可以成功地将表达的GFP定位到转基因植物的叶绿体中.利用β-葡糖苷酸酶(GUS)报告基因替代该入门载体中的GFP基因做试验也得到相似的结果.这说明用目的基因替换该入门载体中的GFP可以构建目的基因的入门载体,然后用通路克隆技术可以快速构建其光诱导型植物表达载体,将表达的目的蛋白定位到转基因植物或组织细胞的叶绿体中.     

猪FcγRIII的原核表达及多克隆抗体的制备

目的：构建猪FcγRIII 基因的原核表达载体,诱导表达重组蛋白,制备鼠抗猪 FcγRIII 抗血清。方法：从质粒pTG19-T-FcγRIII中用PCR方法克隆到编码完整猪FcγRIII蛋白分子的基因片段,将其插入到原核表达载体pET-32a中,构建了猪FcγRIII 原核表达载体pET-FcγRIII ,转化大肠杆菌BL21 (DE3) ,IPTG诱导蛋白表达,经尿素洗涤纯化后,以纯化后的融合蛋白FcγRIII-His 为抗原免疫小鼠,获得抗血清。Western blotting、ELISA 法鉴定获得的抗血清,ELISA 结果显示抗体效价为1∶16000,具有高度特异性,免疫印迹结果显示制备的多抗可以与重组猪FcγRIII蛋白特异性结合。结果：成功构建猪FcγRIII原核表达载体,纯化到融合蛋白FcγRIII-His,用纯化的融合蛋白免疫小鼠制备了多克隆抗体,Western blotting、ELISA 法证实多克隆抗体制备成功。结论：成功获得了猪 FcγRIII 多克隆抗体,为进一步研究猪FcγRIII 蛋白的功能奠定了基础。     

人层粘连蛋白α4链LG3组件的克隆、测序及在原核细胞中的表达

用Trizol法提取胎盘组织总RNA,通过RTPCR方法获得人层粘连蛋白α4链LG3组件的特异扩增产物。将PCR产物克隆入PMD18T载体中,PCR与酶切鉴定正确后进行序列测定。用测序正确的克隆片段与原核表达载体PET28a进行体外重组,构建了LG3的原核表达载体,并在BL21(DE3)菌株中得到了表达。     

重组阳离子抗肿瘤肽AIK的原核表达、纯化及活性测定

利用Gateway克隆技术构建重组抗瘤肽AIK的原核表达体系,建立表达及纯化重组AIK的最优条件,为深入研究和利用AIK奠定基础。首先,设计含AttB重组位点的引物,通过重叠PCR技术扩增出Att B-TEV-FLAG-AIK序列,利用BP重组反应将目的序列TEV-FLAG-AIK克隆到供体载体pDONR223中,构建入门载体,再通过LR重组反应,将目的序列转移到目的载体pDEST15中,构建GST-AIK融合蛋白原核表达质粒。随后,在BL21(DE3)工程菌中优化诱导融合蛋白表达的条件。以谷胱甘肽磁珠纯化GST-AIK融合蛋白,再以rTEV酶切除GST,获得FLAG-AIK重组蛋白。最后以MTS法检测FLAG-AIK对白血病细胞HL-60的细胞毒性。菌液PCR验证和测序分析表明成功构建了重组抗瘤肽AIK的入门质粒和原核表达质粒。在BL21(DE3)工程菌中实现了GST-AIK融合蛋白的高效可溶性表达。并测得在37℃下以0.1 mmol/L IPTG诱导工程菌(OD600=1.0)4 h,重组蛋白表达量占菌体总蛋白的30%以上。经GST亲和层析、rTEV酶切除GST标签及二次GST亲和层析获得纯度高于95%的FLAG-AIK蛋白。MTS法测得所制备的FLAG-AIK蛋白抑瘤活性与化学合成的AIK相当。总之,本课题应用Gateway克隆系统成功构建了抗瘤肽AIK的原核表达质粒,实现了GST-AIK融合蛋白的高效可溶性表达,经亲和层析获得了有生物活性的重组AIK多肽,为后续深入研究和大规模制备奠定了基础。     

人白细胞介素-10在大肠杆菌中的克隆与表达

目的:构建人IL-10原核表达载体,并对表达产物进行鉴定。方法:应用RT-PCR技术从ConA诱导的单核细胞中扩增出IL-10成熟肽cDNA片段,将其克隆到PGEM-T后载体测序,双酶切回收目的片段构建IL-10原核表达载体PET28a-IL10。PET28a-IL10转化大肠杆菌BL21(DE3),经IPTG诱导表达后对其表达产物进行SDS-Page和Western Blot分析。结果:SDS-Page电泳显示IL-10在大肠杆菌中得到了表达,分子量为21000,Western Blot分析显示表达产物可于IL-10多抗特异反应。结论:IL-10在大肠杆菌中成功表达,具有免疫原性。为其进一步生物学研究奠定了基础。     

血管生成抑制因子arresten基因的克隆表达

构建血管生成抑制因子arresten基因的原核表达重组体 ,并进行初步表达。从人胎盘组织中提取总RNA ,经反转录 聚合酶链式反应 (RT PCR)扩增出arresten基因 ;采用T A克隆法 ,将arresten基因克隆入pGEM T载体中 ,经DNA测序确认后 ,构建原核表达重组体pRSET Arr,转化大肠杆菌BL2 1 (DE3) ,用IPTG诱导表达。所获得的arresten基因经测序正确 ,并表达重组蛋白 ,经SDS PAGE分析 ,相对分子量为 2 6ku。构建的原核表达重组体pRSET Arr能高效表达重组arresten蛋白。     

Using a modified TA cloning method to create entry clones

We describe a noncommercial alternative method to create entry clones compatible with all kinds of destination vectors based on an improved TA cloning approach. To generate Gateway T vectors, we first constructed gentamicin- and chloramphenicol-resistant entry vectors designated pGWG and pGWC, respectively. Each entry vector contains an AhdI cassette flanked by attL sites, with each AhdI cassette containing two AhdI restriction enzyme sites spaced by the ccdB killer gene, which is lethal to most Escherichia coli strains. Gateway T vectors can be prepared by simple digestion of these entry vectors with the AhdI enzyme or its isoschizomers. The use of the ccdB gene as a negative selection marker is an important improvement over conventional TA cloning in that it eliminates the necessity of blue/white color screening based on alpha-complementation. Another important improvement that we have implemented is to retail the T vectors using Taq polymerase and dTTP so as to improve the cloning efficiency. Together, these improvements allow TA cloning to realize its full potential. Using Gateway T vectors prepared by this improved method, entry clones for PCR products or restriction enzyme fragments can be created simply, efficiently, and inexpensively while at the same time introducing greater compatibility.     

T载体介导的基于attL核心区LR反应的简化快速Gateway克隆系统

Gateway克隆技术已得到广泛的应用。该技术先通过BP反应将目标片段连到带有完整attL特异识别位点的入门载体,然后与终载体通过LR反应得到表达载体。Gateway克隆方法与传统的酶切连接方法相比有快速简单等优点。但是,BP和LR酶都非常昂贵。本研究首先对3个常用Gateway载体的atts特异位点序列比对发现,attL序列核心交换位点“core attL”的21~22 bp长的碱基是保守和必要的。由此,设计含有core-attL序列的引物,通过PCR克隆得到DNA片段并连入pMD18-T载体,然后进行LR反应,可成功得到目标表达载体,并在保守的位点上正确重组。本研究还对其中一个带有绿色荧光蛋白基因的表达载体转化至烟草,能够正常表达该蛋白质。结果表明,通过将含有attL核心位点基因片段连接到pMD18-T载体上,可以省略BP反应而将目标片段连接到终载体上,节约了反应时间和成本。     

转录因子DREB1A基因的克隆与Gateway克隆技术构建植物表达载体

目的:研究转录因子DREB1A在植物抗渗透胁迫反应中的作用,并探讨利用Gateway克隆技术构建植物表达载体的方法。方法:根据GenBank中登录的DREB1A基因的全长mRNA序列设计引物,克隆了拟南芥的转录因子DREBIA基因。根据Gateway克隆技术的要求,设计含有attB接头的引物,利用高保真的PlatinumpfxDNA聚合酶,通过PCR方法在克隆基因的两端加上B序列。通过BP反应将包含有attB接头的PCR产物克隆到含有attP的donor载体上以产生Entry克隆,通过LR反应将已经重组入Entry载体的DREB1A基因再克隆到pH2GW7双元载体。结果:对重组载体pH2GW7-DREB1A的鉴定结果表明成功构建了DREB1A基因的植物表达载体。结论:利用Gateway克隆技术构建植物表达载体简便易行,该结果为遗传转化研究奠定了基础。     

A Gateway MultiSite recombination cloning toolkit

The generation of DNA constructs is often a rate-limiting step in conducting biological experiments. Recombination cloning of single DNA fragments using the Gateway system provided an advance over traditional restriction enzyme cloning due to increases in efficiency and reliability. Here we introduce a series of entry clones and a destination vector for use in two, three, and four fragment Gateway MultiSite recombination cloning whose advantages include increased flexibility and versatility. In contrast to Gateway single-fragment cloning approaches where variations are typically incorporated into model system-specific destination vectors, our Gateway MultiSite cloning strategy incorporates variations in easily generated entry clones that are model system-independent. In particular, we present entry clones containing insertions of GAL4, QF, UAS, QUAS, eGFP, and mCherry, among others, and demonstrate their in vivo functionality in Drosophila by using them to generate expression clones including GAL4 and QF drivers for various trp ion channel family members, UAS and QUAS excitatory and inhibitory light-gated ion channels, and QUAS red and green fluorescent synaptic vesicle markers. We thus establish a starter toolkit of modular Gateway MultiSite entry clones potentially adaptable to any model system. An inventory of entry clones and destination vectors for Gateway MultiSite cloning has also been established (www.gatewaymultisite.org).     

Construction of two Gateway vectors for gene expression in fungi

We report the construction of two Gateway fungal expression vectors pCBGW and pGWBF. The pCBGW was generated by introducing an expression cassette, which consists of a Gateway recombinant cassette (attR1-Cmr-ccdB-attR2) under the control of fungal promoter PgpdA and a terminator TtrpC, into the multiple cloning site of fungal vector pCB1004. The pGWBF is a binary vector, which was generated from the plant expression vector pGWB2 by replacing the CaMV35S promoter with PgpdA. The pGWBF can be transformed into fungi efficiently with Agrobacterium-mediated transformation. The applicability of two newly constructed vectors was tested by generating the destination vectors pGWBF-GFP and pCBGW-GFP and examining the expression of GFP gene in Trichoderma viride and Gibberella fujikuroi, respectively. Combining with the advantage of Gateway cloning technology, pCBGW and pGWBF will be useful in fungi for large-scale investigation of gene functions by constructing the interested gene destination/expression vectors in a high-throughput way.     

Development of a novel Gateway-based vector system for efficient, multiparallel protein expression in Escherichia coli

We describe a cloning and expression system which is based on the Escherichia coli T7 expression system and Gateway recombination technology. We have produced numerous destination vectors with selected fusion tags and an additional set of entry vectors containing the gene of interest and optional labeling tags. This powerful system enables us to transfer a cDNA to several expression vectors in parallel and combine them with various labeling tags. To remove the attached amino terminal tags along with the unwanted attB1 site, we inserted PreScission protease cleavage sites. In contrast to the commercially available destination vectors, our plasmids provide kanamycin resistance, which can be an advantage when expressing toxic proteins in E. coli. Some small-scale protein expression experiments are shown to demonstrate the usefulness of these novel Gateway vectors. In summary, this system has some benefits over the widely used and commercially available Gateway standard system, and it enables many different combinations for expression constructs from a single gene of interest.     

High-throughput gateway bicistronic retroviral vectors for stable expression in mammalian cells: exploring the biologic effects of STAT5 overexpression

Stable expression of cloned genes in mammalian cells has been achieved in the past by retroviral transduction using bicistronic retroviral vectors. In these vectors, the use of an Internal Ribosome Entry Site (IRES) allows simultaneous expression of a protein of interest and a fluorescence marker. However, traditional cDNA cloning in these vectors is often difficult. Here we report the construction of a high-throughput retroviral vector using the Invitrogen "Gateway" Cloning system. The Gateway recombination sequences (attR) flanking the ccdB and chloramphenicol resistance genes were incorporated at the 5' of the IRES of pMX-IRES-GFP, -CD2, or -CD4 vectors. Through recombination, these vectors can acquire cDNAs coding for genes of interest, which will result in simultaneous expression of the recombined gene and the marker protein. We constructed Gateway bicistronic vectors coding for the erythropoietin receptor (EpoR) and GFP, CD4, or CD2. Epo-dependent proliferation assays and analysis of Jak2-dependent EpoR cell-surface expression showed that these vectors were able to function indistinguishable from the original pMX-EpoR-IRES-GFP. The expression levels of the genes cloned upstream the IRES were proportional to the levels of expression of GFP, which was cloned downstream of the IRES. We used the same approach and generated Ba/F3 cells that overexpress STAT5a, STAT5b, or a constitutively active form of STAT5. Overexpression of STAT5 lead to a significant effect on the intrinsic adherence to plastic of these cells, but did not change their proliferative responses to cytokines. We discuss possible applications of the new vectors for cell signaling and expression cloning.     

A Modified MultiSite Gateway Cloning Strategy for Consolidation of Genes in Plants

The genome information is offering opportunities to manipulate genes, polygenic characters and multiple traits in plants. Although a number of approaches have been developed to manipulate traits in plants, technical hurdles make the process difficult. Gene cloning vectors that facilitate the fusion, overexpression or down regulation of genes in plant cells are being used with various degree of success. In this study, we modified gateway MultiSite cloning vectors and developed a hybrid cloning strategy which combines advantages of both traditional cloning and gateway recombination cloning. We developed Gateway entry (pGATE) vectors containing attL sites flanking multiple cloning sites and plant expression vector (pKM12GW) with specific recombination sites carrying different plant and bacterial selection markers. We constructed a plant expression vector carrying a reporter gene (GUS), two Bt cry genes in a predetermined pattern by a single round of LR recombination reaction after restriction endonuclease-mediated cloning of target genes into pGATE vectors. All the three transgenes were co-expressed in Arabidopsis as evidenced by gene expression, histochemical assay and insect bioassay. The pGATE vectors can be used as simple cloning vectors as there are rare restriction endonuclease sites inserted in the vector. The modified multisite vector system developed is ideal for stacking genes and pathway engineering in plants.     

An Alternative Approach in Gateway® Cloning when the Bacterial Antibiotic Selection Cassettes of the Entry Clone and Destination Vector are the Same

The Gateway^® recombination technology has revolutionized the method of gene cloning for functional analyses and high-throughput ORFeome projects. In general, Gateway cloning is highly efficient because after LR recombination and bacterial transformation, only cells containing the recombinant destination clone are selected on an antibiotic selection plate. However, when the antibiotic resistance gene for bacterial selection is the same in the entry and destination vectors, the direct selection of recombinant destination clones on an antibiotic plate is difficult. Here, we demonstrate an efficient and comprehensive approach to obtain positive destination clones directly on an antibiotic selection plate in this situation. The strategy involves polymerase chain reaction (PCR)-mediated amplification of the entry clone using entry vector-specific primers that bind outside the attL sequences and the subsequent use of this purified PCR product for LR recombination with the destination vector. Our results suggest that cloning of linear DNA fragments into circular destination vectors through LR recombination is an efficient method for inserts up to 7 kb in size. Using this approach, the yield of colony PCR positive destination clones was 100 % for genes of various sizes tested in our experiments.